Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction In Australia, atopic dermatitis (AD) has been estimated to affect approximately 30% of children and 10%–15% of adults [1]. The estimated lifetihme prevalence of AD in Australia is approximately 16%, with one in five patients with AD having moderate-to-severe disease [2].
In The Lancet, Kim Papp and colleagues 1 Papp KA Weinberg M Morris A Reich K IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021; 397: 1564-1575 report the efficacy of nanobodies, a novel molecular technology, in patients with moderate to severe chronic plaque-type psoriasis.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
